Curated research to understand technology benefits, comparisons, and limitations, prioritizing studies that identify devices or brands in our portfolio.
Brands in our portfolio2023 · Tantrakul V et al.
CPAP in high-risk pregnancy with OSA
Treatment of obstructive sleep apnea in high risk pregnancy: a multicenter randomized controlled trial
Respiratory research
Open-label randomised trial · Three hospitals · 310 participants in the primary analysis
Findings: Diastolic blood pressure decreased by an average of 2.2 mmHg. Preeclampsia occurred in 13.1% of the CPAP group vs 22.3% with usual care.
Points to consider: 96.5% were recruited in the first trimester; this was not a trial of starting CPAP specifically in trimester III. Mean adherence was 2.5 hours/night. Findings apply to the high-risk OSA population studied.
Device & relevance: Philips Respironics REMstar Auto M / DreamStation named in the methods; the currently offered model needs to be matched.
DOI: 10.1186/s12931-023-02445-y
General clinical evidence2023 · Facco FL et al.
PAP in pregnancy: inconsistent findings
A trial of positive airway pressure for the treatment of sleep apnea in pregnancy
American journal of obstetrics & gynecology MFM
Randomised trial · 89 participants with OSA and obesity · Assessment at 28–31 weeks
Findings: There was no significant difference in the primary composite cardiometabolic risk outcome between treatment and control groups.
Points to consider: Treatment adherence was low; the control design changed between phases. Read this study alongside the Tantrakul trial, rather than selecting only positive findings.
Device & relevance: Brand/model match has not been verified.
DOI: 10.1016/j.ajogmf.2022.100840
General clinical evidence2016 · McEvoy RD et al.
CPAP, OSA symptoms, and cardiovascular outcomes
CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
The New England journal of medicine
SAVE · Randomised trial · 2,717 adults with OSA and cardiovascular disease
Findings: CPAP improved snoring, daytime sleepiness, mood, and health-related quality of life.
Points to consider: Major cardiovascular events were not reduced in this population over an average 3.7 years; average use was 3.3 hours/night.
Device & relevance: CPAP evidence in OSA; the identity of the model offered must be assessed separately from the study findings.
DOI: 10.1056/nejmoa1606599
No matching studies. Try another term or select all journals.
Reading evidence in context.
A model label means the study names a device matching the catalog. A brand label identifies the same brand, while the offered model still needs matching. Procedural and general clinical evidence provide context; findings do not automatically establish benefits for every device.
Summaries support education and discussion with healthcare professionals. Links open original publications; full-text availability depends on publisher access. Curated September 9, 2026.
